The hospital needs 176 healthy volunteers for the trial
The UMCG is the only hospital in Europe to investigate a new candidate vaccine against Covid-19, reports the GIC. There is quite a bit of hope for the AKS-452 vaccine from Akston Biosciences in the United States. For the study, the UMCG is looking for 176 healthy volunteers between the ages of 18 and 65 who want to be vaccinated with the candidate vaccine.
The aim of the research is to investigate the safety, tolerability and response of the immune system to the vaccine, which uses a genetically-engineered protein from the actual Coronavirus. The vaccine also has a liquid or adjuvant to hopefully enhance any immune response. Anyone with a biology degree can read how it works here.
The vaccine has already been extensively tested in animal models for COVID-19 infections, in which it has been shown to be effective and safe. The next phase is to investigate the safety, tolerability and response of the immune system to the vaccine in humans.
The UMCG is looking for 176 healthy volunteers older than 18 and younger than 65 years, who have never had a SARS-CoV-2 infection or received a (candidate) vaccine against corona before. Study participants will receive one or two doses of the candidate vaccine to determine the dose at which you have sufficient antibodies in your body. Participants will not lose the right to receive another Coronavirus vaccine at a later date.